中文摘要：

在哺乳动物中,肝X受体(LXR)是调节脂质平衡的关键物质。这类转录因子通过组织依赖的方式控制着一系列基因的表达,而这些基因能够调节胆固醇的吸收、转运、外流和排泄。LXR属于配体激活细胞受体,同时也是潜在的药物靶点,通过对LXR通路的操纵将有助于他汀类药物作用的发挥,而LXR配体已经用于动脉粥样硬化和高脂血症的早期临床试验中。同时,针对LXR及其靶向基因的研究为治疗以脂质代谢为核心的疾病(包括动脉粥样硬化和阿尔茨海默病)治疗提供了可能。

英文摘要：

In mammals, the liver X receptor (LXR) is the key material in lipid balance. This type of transcription factor controls a series of genes' expression by organizational dependence, and these genes can regular cholesterol's uptake, transport, efflux and excretion. LXR belongs to the receptor ligands activate cells, as well as potential drug targets, through the manipulation of LXR pathways will help play a role of statins, and LXR ligand has been used for early clinical trials of atherosclerosis and hyperlipidemia. Meanwhile, new strategies for the pharmacological manipulation of LXR and their target genes offer promise for the treatment of human diseases in which lipids have a central role, including atherosclerosis and Alzheimer disease.